At a PAINWeek 2012 presentation investigators reported that immediate-release opioids are acceptable to use as supplemental analgesia in certain situations, according to the Monthly Prescribing ...

2025 FEB 27 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News-- New research on Opioids is the subject of a report. According to news reporting originating in New Albany, Ohio, ...

Nutriband Inc. (NASDAQ:NTRB) is a pharmaceutical company with a specific focus on developing a portfolio of transdermal pharmaceutical products. The company’s lead product under development is AVERSA™ ...

September 28, 2010 (Las Vegas, Nevada) — A transdermal application system containing the partial μ-opioid receptor agonist buprenorphine showed analgesic efficacy in the treatment of low back pain in ...

Credit: Alvogen, Inc. Fentanyl is an opioid agonist indicated for the management of severe or persistent pain in opioid-tolerant patients. At this time, Alvogen Inc has received 1 serious adverse ...

ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it ...

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments Nutriband is partnering with ...

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology ...

Nutriband (NTRB) files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for ...

Opioid analgesics remain the most effective available therapy, but side effects limit their use. The most important advances in the pharmacology of opioids are related to new formulations and novel ...